Physician
Mercy Hospital Rogers
Mercy Hospital Rogers was paid $14.20M by Medicaid between Jan 2018 and Dec 2024, across 339 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 11% of everything it billed.
33Billing provider infoMERCY HOSPITAL ROGERS
ROGERS, AR 72758
ROGERS, AR 72758
33aNPI1316902414assigned 04/20/2006
33bProvider typeInterventional Pain Medicine Physician
28Total paid$14.20M
24GClaims724,639
24DCodes billed339
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Arkansas
Rank by total paid#1 of 10
Median peer was paid$5K
This provider vs. median2,596×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILCHER, GRETA controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 116,450 | $1.79M | |
| 2019 | 123,247 | $2.02M | |
| 2020 | 95,716 | $1.91M | |
| 2021 | 91,089 | $2.00M | |
| 2022 | 95,283 | $2.29M | |
| 2023 | 112,298 | $2.44M | |
| 2024incomplete | 90,556 | $1.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 11% | 38,669 | 10,880 | $1.61M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 6,335 | 5,799 | $825K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 6,848 | 6,231 | $599K |
| 80053 | Comprehensive metabolic panel | 3.5% | 28,167 | 23,354 | $501K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.5% | 4,043 | 2,017 | $499K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 5,642 | 4,125 | $433K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.8% | 3,537 | 3,316 | $399K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 6,566 | 5,228 | $390K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.5% | 3,306 | 3,160 | $357K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 45,982 | 35,975 | $321K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.0% | 6,109 | 5,841 | $279K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 18,326 | 14,489 | $274K |
327 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.8% | 1,614 | $263K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 19,650 | $250K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.7% | 1,076 | $238K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.7% | 675 | $236K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 1,978 | $201K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 18,482 | $180K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 8,770 | $174K |
| 59025 | Fetal non-stress test | 1.2% | 1,017 | $174K |
| 97161 | 1.1% | 3,013 | $157K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 939 | $145K |
| 99283 | Emergency room visit (moderate) | <1% | 2,634 | $141K |
| 93976 | <1% | 2,461 | $135K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,142 | $128K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,152 | $128K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,111 | $126K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,910 | $122K |
| 99285 | Emergency room visit (most serious) | <1% | 5,003 | $118K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,144 | $115K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,923 | $112K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 864 | $105K |
| 87428 | <1% | 1,710 | $104K | |
| 83880 | <1% | 4,559 | $101K | |
| 87081 | <1% | 11,317 | $96K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 453 | $94K |
| 84484 | <1% | 11,100 | $90K | |
| 81025 | <1% | 9,923 | $82K | |
| 87653 | <1% | 1,855 | $81K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,781 | $81K |
| 80306 | <1% | 4,958 | $81K | |
| 99284 | Emergency room visit (serious) | <1% | 2,425 | $79K |
| 80050 | General health panel | <1% | 2,202 | $77K |
| 83690 | <1% | 11,274 | $75K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,370 | $73K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 9,026 | $72K |
| 82947 | <1% | 4,769 | $68K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 698 | $68K |
| 86901 | <1% | 3,392 | $66K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 350 | $66K |
| 81001 | <1% | 19,642 | $65K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,258 | $62K |
| 97001 | <1% | 1,965 | $60K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,988 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 805 | $54K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,471 | $52K |
| 70498 | <1% | 354 | $51K | |
| 82565 | <1% | 3,502 | $50K | |
| 12001 | <1% | 256 | $50K | |
| 80081 | <1% | 586 | $50K | |
| 87070 | <1% | 4,359 | $49K | |
| 70496 | <1% | 347 | $49K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,228 | $48K |
| 76801 | <1% | 1,503 | $47K | |
| 87077 | <1% | 5,760 | $46K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,402 | $45K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 944 | $44K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,587 | $43K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 157 | $43K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 879 | $40K |
| 76830 | Ultrasound, transvaginal | <1% | 779 | $39K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,822 | $39K |
| 72141 | <1% | 179 | $37K | |
| 82962 | <1% | 5,470 | $35K | |
| 86140 | <1% | 7,335 | $34K | |
| 73562 | <1% | 1,129 | $34K | |
| 87186 | <1% | 5,741 | $33K | |
| 80076 | <1% | 3,194 | $33K | |
| 73630 | <1% | 1,263 | $32K | |
| 83735 | <1% | 6,704 | $32K | |
| 82803 | <1% | 1,959 | $32K | |
| 71250 | <1% | 530 | $32K | |
| 0240U | <1% | 271 | $32K | |
| 83605 | <1% | 3,284 | $31K | |
| 87040 | <1% | 2,349 | $30K | |
| 85610 | <1% | 9,879 | $30K | |
| 72100 | <1% | 1,148 | $29K | |
| 82077 | <1% | 2,071 | $29K | |
| 93971 | <1% | 816 | $29K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 451 | $28K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,845 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,480 | $27K |
| 94060 | <1% | 772 | $27K | |
| 73610 | <1% | 1,288 | $27K | |
| 86850 | <1% | 2,673 | $27K | |
| 85379 | <1% | 2,931 | $26K | |
| 97162 | <1% | 383 | $26K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 581 | $25K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,176 | $25K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 86 | $24K |
| 73030 | <1% | 983 | $24K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 927 | $24K |
| 81003 | <1% | 9,430 | $24K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 597 | $24K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,847 | $24K |
| 12011 | <1% | 105 | $23K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,170 | $23K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 175 | $23K |
| 97165 | <1% | 502 | $22K | |
| 84112 | <1% | 306 | $22K | |
| 73130 | <1% | 902 | $21K | |
| 84145 | <1% | 1,129 | $21K | |
| 80143 | <1% | 1,180 | $21K | |
| 84702 | <1% | 2,120 | $20K | |
| 83655 | <1% | 1,332 | $20K | |
| 80320 | <1% | 1,609 | $19K | |
| 86900 | <1% | 3,278 | $19K | |
| 80179 | <1% | 1,119 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,781 | $19K |
| 80074 | <1% | 411 | $18K | |
| 73110 | <1% | 806 | $18K | |
| 76642 | <1% | 680 | $17K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 166 | $17K |
| 11043 | <1% | 108 | $17K | |
| 87147 | <1% | 1,885 | $17K | |
| 70486 | <1% | 157 | $17K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 410 | $16K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,423 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,858 | $16K |
| 93017 | <1% | 1,079 | $14K | |
| 74018 | <1% | 665 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,427 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,631 | $14K |
| 80061 | Lipid panel | <1% | 1,827 | $13K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,640 | $13K |
| 74022 | <1% | 553 | $13K | |
| 87631 | <1% | 142 | $12K | |
| 87807 | <1% | 1,001 | $12K | |
| 94729 | <1% | 650 | $12K | |
| 94726 | <1% | 646 | $11K | |
| 87075 | <1% | 1,086 | $11K | |
| 85652 | <1% | 4,994 | $11K | |
| 85730 | <1% | 2,214 | $11K | |
| 85027 | <1% | 1,774 | $10K | |
| 90715 | <1% | 703 | $10K | |
| 80329 | <1% | 916 | $10K | |
| 87210 | <1% | 1,844 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,891 | $9K |
| 82550 | <1% | 1,601 | $8K | |
| 76536 | <1% | 210 | $8K | |
| 71020 | <1% | 589 | $8K | |
| 87641 | <1% | 453 | $8K | |
| 73502 | <1% | 217 | $8K | |
| 62323 | <1% | 53 | $7K | |
| 87205 | <1% | 2,168 | $7K | |
| 87088 | <1% | 860 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 715 | $7K |
| 87493 | <1% | 243 | $7K | |
| 87899 | <1% | 729 | $7K | |
| 84146 | <1% | 334 | $7K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 72 | $6K |
| 93226 | <1% | 176 | $6K | |
| 72040 | <1% | 214 | $6K | |
| 83970 | <1% | 238 | $5K | |
| 87634 | <1% | 62 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,362 | $5K |
| 97003 | <1% | 256 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,093 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,186 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,597 | $5K |
| 87340 | <1% | 395 | $4K | |
| 71010 | <1% | 622 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,549 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,751 | $4K |
| 77066 | Tomosynthesis, mammo | <1% | 72 | $4K |
| 87045 | <1% | 389 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,256 | $4K |
| 86039 | <1% | 395 | $3K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 31 | $3K |
| 12002 | <1% | 12 | $3K | |
| 29125 | <1% | 15 | $3K | |
| 36600 | <1% | 221 | $3K | |
| 95811 | <1% | 25 | $3K | |
| 77080 | <1% | 58 | $3K | |
| 87046 | <1% | 391 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 103 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 427 | $3K |
| 86592 | <1% | 595 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 187 | $3K |
| 93225 | <1% | 144 | $2K | |
| 83516 | <1% | 202 | $2K | |
| 87400 | <1% | 140 | $2K | |
| 76770 | <1% | 62 | $2K | |
| 99152 | <1% | 403 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,831 | $2K |
| 86762 | <1% | 138 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,156 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,858 | $2K |
| 84439 | <1% | 214 | $2K | |
| 73090 | <1% | 81 | $2K | |
| 86038 | <1% | 157 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,031 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 128 | $2K |
| 80164 | <1% | 218 | $2K | |
| 84156 | <1% | 564 | $2K | |
| 82150 | <1% | 292 | $2K | |
| 82570 | <1% | 437 | $2K | |
| 82010 | <1% | 273 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 44 | $2K |
| 94761 | <1% | 552 | $2K | |
| 82784 | <1% | 213 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 40 | $2K |
| 93975 | <1% | 28 | $2K | |
| 73560 | <1% | 30 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,147 | $2K |
| 51798 | <1% | 14 | $1K | |
| 94760 | <1% | 269 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,985 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,202 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,640 | $1K |
| 82140 | <1% | 234 | $1K | |
| A9270 | Non-covered item or service | <1% | 4,298 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,712 | $1K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 138 | $945.16 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,889 | $929.59 |
| 97597 | <1% | 51 | $915.42 | |
| 86003 | <1% | 13 | $887.74 | |
| 74000 | <1% | 54 | $880.50 | |
| 73590 | <1% | 37 | $860.15 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 53 | $838.25 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 26 | $800.83 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,144 | $778.96 |
| 73070 | <1% | 44 | $770.47 | |
| 82607 | <1% | 145 | $756.90 | |
| 86803 | <1% | 56 | $749.94 | |
| C1769 | Guide wire | <1% | 15 | $746.59 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,171 | $706.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 225 | $697.39 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,990 | $696.95 |
| 73140 | <1% | 31 | $616.39 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 55 | $552.62 |
| 86481 | <1% | 12 | $552.47 | |
| 82397 | <1% | 31 | $545.26 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $534.79 |
| 84100 | <1% | 193 | $530.94 | |
| 86200 | <1% | 56 | $530.37 | |
| 82728 | <1% | 49 | $486.50 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 65 | $478.98 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 175 | $436.08 |
| 71101 | <1% | 12 | $425.32 | |
| 87328 | <1% | 38 | $425.17 | |
| 87329 | <1% | 38 | $416.85 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 37 | $401.21 |
| 89055 | <1% | 37 | $398.00 | |
| 84402 | <1% | 12 | $386.69 | |
| 84703 | <1% | 28 | $367.75 | |
| 74230 | <1% | 13 | $367.05 | |
| 82105 | <1% | 31 | $364.77 | |
| 84403 | <1% | 12 | $358.70 | |
| 72170 | <1% | 17 | $344.36 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 12 | $340.52 |
| 86696 | <1% | 12 | $311.50 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 636 | $310.79 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 104 | $308.01 |
| 0353U | <1% | 376 | $303.24 | |
| 83540 | <1% | 107 | $286.75 | |
| 92611 | <1% | 13 | $281.22 | |
| 83615 | <1% | 48 | $280.47 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 214 | $268.14 |
| 82746 | <1% | 81 | $255.12 | |
| 82533 | <1% | 14 | $225.30 | |
| 83520 | <1% | 15 | $221.88 | |
| 87425 | <1% | 16 | $180.18 | |
| Q3014 | Telehealth originating site facility fee | <1% | 113 | $169.55 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 318 | $156.67 |
| 86695 | <1% | 12 | $152.71 | |
| 97014 | <1% | 1,142 | $144.15 | |
| 82247 | <1% | 22 | $143.40 | |
| 86923 | <1% | 14 | $135.80 | |
| 82330 | <1% | 15 | $132.09 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $130.00 |
| 87185 | <1% | 29 | $128.82 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 208 | $128.06 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 140 | $125.42 |
| 85014 | <1% | 31 | $112.67 | |
| 80177 | <1% | 14 | $108.54 | |
| 87640 | <1% | 12 | $101.34 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 470 | $100.08 |
| 93242 | <1% | 12 | $88.02 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 601 | $75.75 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 153 | $72.88 |
| 82248 | <1% | 15 | $71.70 | |
| 85018 | <1% | 15 | $68.52 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 55 | $54.35 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,486 | $49.59 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 94 | $49.05 |
| 96376 | <1% | 1,719 | $43.87 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 17 | $43.52 |
| 84550 | <1% | 14 | $42.90 | |
| G0378 | Hospital observation service, per hour | <1% | 235 | $41.78 |
| 36416 | <1% | 18 | $40.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 38 | $37.57 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 417 | $23.65 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 47 | $21.76 |
| 76981 | <1% | 12 | $19.48 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 29 | $19.36 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 142 | $18.09 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 710 | $17.60 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 761 | $11.53 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 27 | $11.40 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 55 | $11.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 41 | $10.38 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 141 | $8.74 |
| 97010 | <1% | 711 | $8.37 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 28 | $7.68 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 217 | $2.19 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 283 | $0.26 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 253 | $0.20 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 74 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 85 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 16 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 31 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 12 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 44 | $0.00 |
| 97116 | 0% | 19 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 138 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 142 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 37 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 53 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 247 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 220 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 92 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 12 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 35 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 153 | $0.00 |
| 97016 | 0% | 38 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILCHER, GRETA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Mercy Clinic Fort Smith Communities | Fort Smith, AR | $24.10M |
| Mercy Hospital Fort Smith | Fort Smith, AR | $22.48M |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $8.38M |
| Mercy Clinic Fort Smith Communities | Fort Smith, AR | $2.28M |
| Mercy Hospital Rogers | Rogers, AR | $1.83M |
| Mercy Clinic Fort Smith Communities | Fort Smith, AR | $1.62M |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $318K |
| Mercy Hospital Fort Smith | Fort Smith, AR | $298K |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $207K |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $104K |
| Mercy Health Northwest Arkansas Communities | Bella Vista, AR | $86K |
| ST Edward Mercy Foundation | Fort Smith, AR | $74K |
| Mercy Health Northwest Arkansas Communities | Rogers, AR | $26K |
| Mercy Hospital Fort Smith | Fort Smith, AR | $127.47 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.